allogeneic– tag –
-
Kincell Bio Unveils Scalable Allogeneic Cell Therapy Manufacturing Platform for Large-Scale Production with Closed-System Automation
Kincell Bio USA Overview Kincell Bio has launched a scalable allogeneic cell therapy manufacturing platform designed for large-volume production, efficient cell expansion, and closed-system automation. This platform supports diverse cell... -
Kolon TissueGene’s Cell and Gene Therapy TG-C Fails to Meet Primary Endpoints in Phase 3 Knee Osteoarthritis Trial
Fierce Biotech USA Overview Kolon TissueGene's cell and gene therapy TG-C failed to achieve its co-primary endpoints in the Phase 3 ACTiVION-II trial for knee osteoarthritis, showing no significant improvement in pain or function compare... -
Kincell Bio Scales Allogeneic Cell Therapy Manufacturing, Bridging Early Clinical to Commercial Supply
Kincell Bio USA Overview Kincell Bio, a specialized CDMO for allogeneic cell therapies, is advancing scalable manufacturing solutions to accelerate product commercialization. The company's expertise focuses on developing efficient proces... -
FUJIFILM Cellular Dynamics Opens iPSC Manufacturing Facility, Made Scientific & Pluristyx Announce iPSC Partnership Expansion
openPR.com USA Overview According to openPR.com, FUJIFILM Cellular Dynamics opened a new iPSC development and manufacturing facility in Madison in May 2026, significantly expanding its induced pluripotent stem cell production capacity. F... -
Kincell Bio Strengthens GMP Manufacturing for Autologous & Allogeneic Cell Therapies Across Diverse Modalities from US Two Sites
Kincell Bio USA Overview Kincell Bio announced enhanced GMP manufacturing services for both autologous and allogeneic cell therapy programs, leveraging two advanced facilities in Gainesville, Florida, and Research Triangle Park, North Ca... -
Allogene’s ALLO-316 Allogeneic CAR T Achieves First Durable Remissions with 31% ORR in Phase 1 Metastatic Renal Cell Carcinoma Trial
BioSpace USA Overview Allogene Therapeutics announced compelling Phase 1 results for ALLO-316, a CD70-targeted allogeneic CAR T therapy, demonstrating a 31% confirmed objective response rate and the first durable remissions in metastatic... -
Wugen Rebrands as Allotera, Closes $35 Million Financing Round to Accelerate Off-the-Shelf Cell Therapy Development for Cancer and Autoimmune Diseases
Cellgenetherapyreview.com USA Overview On July 10, 2026, Wugen announced its rebranding to Allotera and the successful completion of a $35 million financing round. This rebranding and capital infusion represent a significant strategic st... -
Gene and Cell Therapy See Multiple Breakthroughs: Orca Bio’s TREGZI Receives FDA Approval, Vertex/CRISPR’s CASGEVY Expands Pediatric Indication, and Carsgen’s Satri-cel Gains China Approval
YouTube (LucidQuest) USA, China Overview According to a July 9, 2026, gene and cell therapy update, Orca Bio's precision engineered cell therapy, TREGZI, received FDA approval, offering a new option for matched donor allogeneic transplan... -
Century Therapeutics Unveils Preclinical Data for iPSC-Derived Islet Replacement Therapy CNTY-813 for Type 1 Diabetes, Aiming for Immunosuppression-Free Treatment via Allo-Evasion™ 5.0 Technology and H2 2026 IND Filing
GlobeNewswire (Century Therapeutics) USA Overview Century Therapeutics announced that preclinical data for CNTY-813, its iPSC-derived islet replacement therapy for Type 1 Diabetes, will be presented at EASD 2026 and the Breakthrough T1D ... -
CAR T-Cell Therapy Broadens Horizons: Expanding Indications and Manufacturing Advances Drive Wider Access Beyond Oncology to Autoimmune Diseases
AJMC USA Overview This review article comprehensively discusses how CAR T-cell therapy is entering an era of broader adoption, driven by clinical advancements, expanding indications, and enhanced manufacturing efficiency. Building on ini...
